Effects of the Oral Contraceptive Combination 0.150 mg Desogestrel+0.020 mg Ethinylestradiol on Serum Lipids, SHBG, Glycosylated Proteins and Plasma Antithrombin III Activity in Healthy Women

References

• Stadel B V. Oral contraceptives and cardiovascular disease (first of two parts). New Engl J Med 1981; 305: 612–18
   PubMed Web of Science ®Google Scholar
• Mammen E F. Oral contraceptives and blood coagulation: a critical review. Am J Obstet Gynecol 1982; 142: 781–90
   PubMed Web of Science ®Google Scholar
• Stolley P D., Tonascia J A., Tockman M S., Sartwell P E., Rutledge A H., Jacobs M P. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol 1975; 102: 197–208
   PubMed Web of Science ®Google Scholar
• Meade T W., Greenberg G, Thompson S G. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50-and 30-microgram oestrogen preparations. Br Med J 1980; 280: 1157–61
   PubMed Web of Science ®Google Scholar
• Stadel B V. Oral contraceptives and cardiovascular disease (second of two parts). New Engl J Med 1981; 305: 672–7
   PubMed Web of Science ®Google Scholar
• Bergink E W., Borglin N E., Klottrup P, Liukko P. Effects of desogestrel and levonorgestrel in low-dose oestrogen oral contraceptives on serum lipoproteins. Contraception 1982; 25: 477–85
   Google Scholar
• Wynn V, Niththyananthan R. The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins. Am J Obstet Gynecol 1982; 142: 766–71
   PubMed Web of Science ®Google Scholar
• Avogaro P, Cazzalato G, Bittolo Bon G., Quinci G G. High and low high-density lipoproteins: clinical implications. Nutr Metab (Suppl 1) 1980; 24: 34–44
   Google Scholar
• Spellacy W N., Buhi W C., Birk S. Carbohydrate metabolism prospectively studied in women using a low-estrogen oral contraceptive for six months. Contraception 1979; 20: 137–48
   PubMed Web of Science ®Google Scholar
• McFarland K F., Catalano E W., Day J F., Thorpe S R., Baynes J W. Nonenzymatic glycosylation of serum proteins in diabetes mellitus. Diabetes 1979; 28: 1011–14
   PubMed Web of Science ®Google Scholar
• El Makhzangy M N., Wynn V, Lawrence D M. Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids. Clin Endocrinol 1979; 10: 39–45
   PubMedGoogle Scholar
• Trinder P. Simple turbidimetric method for the determination of serum cholesterol. Ann Clin Biochem 1969; 63: 165–6
   Google Scholar
• Bürstein M, Scholnick H R., Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970; 11: 583–95
   PubMed Web of Science ®Google Scholar
• Lopes-Virella M F., Stone P, Ellis S, Colwell J A. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 1977; 23: 882–4
   PubMed Web of Science ®Google Scholar
• Mickelson K E., Petra P H. A filter assay for the sex steroid binding proteins of human serum. FEBS Lett 1974; 44: 34–8
   PubMed Web of Science ®Google Scholar
• Bergink E W., Holma P, Pyörälä T. Effects of oral contraceptive combinations containing levonorgestrel or desogestrel on serum proteins and androgen binding. Scand J Clin Lab Invest 1981; 41: 663–8
   PubMed Web of Science ®Google Scholar
• Kostner G M., Avogaro P, Bon G B., Cazzolato G, Quinci G B. Determination of high-density lipoproteins: screening methods compared. Clin Chem 1979; 25: 939–42
   PubMed Web of Science ®Google Scholar
• Bergink E W., Kloosterboer H J., Lund L, Nummi S. Effects of levonorgestrel and desogestrel in low-dose oral contraceptive combinations on serum lipids, apolipopro-teins A-I and B and glycosylated proteins. Contraception 1984; 30: 61–72
   PubMed Web of Science ®Google Scholar
• Hesse R, Tritschler W, Castelfranchi G, Bablok W. Antithrombin III: Referenzwerte mit einem chromogenen Substrat (Chromozym TH). Blut 1981; 42: 227–34
   PubMedGoogle Scholar
• Havekes L, van Gent C M., Stegerhoek C I., Arntzenius A C., Hessel L W. High-density lipoprotein cholesterol and apolipoprotein A-I levels in 32—33-year-old women on steroid contraceptives-differences between two frequently used low-estrogen pills. Clin Chim Acta 1981; 116: 223–9
   PubMed Web of Science ®Google Scholar
• Bergink E W., Bos E S., Kloosterboer H J., Lund L, Nummi S, van der Vies J. Oral contraceptives and lipoproteins, P A. van Keep, H Kopera. International Health Foundation, Brussels 1983; 52–63
   Google Scholar
• Cullberg G, Samsioe G, Andersen R F., et al. Two oral contraceptives, efficacy, serum proteins, and lipid metabolism. A comparative multicenter study on a triphasic and a fixed dose combination. Contraception 1982; 26: 229–43
   PubMed Web of Science ®Google Scholar
• Cullberg G, Dovre P A., Lindstedt G, Steffensen K. On the use of plasma proteins as indicators of the metabolic effects of combined oral contraceptives. Acta Obstet Gynecol Scand (Suppl) 1982; 111: 47–54
   Google Scholar
• Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516–30
   PubMedGoogle Scholar